

CLAIMS

1. An immunoconjugate comprising an antibody which:

- 5 a) binds to human and *Macaca fascicularis* LAMP1 proteins; and
 b) is linked or conjugated to at least one growth inhibitory agent.

2. The immunoconjugate according to claim 1, wherein said at least one growth inhibitory agent is

- 10 (i) a cytotoxic agent selected from the group consisting of enzymes other than pokeweed antiviral protein; antibiotics other than bleomycin and mitomycin; toxins of bacterial, fungal, or animal origin or of plant origin other than abrin and ricin, including fragments and/or variants thereof ; a drug or a pro-drug of a compound consisting in an anti-tubulin agent, a maytansinoid or maytansinoid analog, a
15 taxoid or taxane other than paclitaxel (Taxol), a vinca-alkaloid other than vindesine, vincristine and vinblastine, a cryptophycin derivative, an auristatin or dolastatin analog; a DNA alkylating agent other than BCNU and cyclophosphamide, a tomaymycin or pyrrolobenzodiazepine derivative, a CC-1065 or CC-1065 analog; a leptomycin derivative; a topoisomerase II inhibitors
20 other than doxorubicin (adriamycin) and etoposide, a RNA polymerase II inhibitor, alpha-amanitin, or
 (ii) a radioactive isotope selected from the group consisting of At²¹¹, Ac²²⁵, Bi²¹³, Pb²¹², Er¹⁶⁹, I¹²⁴, I¹²⁵, In¹¹¹, P³², Re¹⁸⁶, Sm¹⁵³, Sr⁸⁹, Zr⁸⁹, Tc^{99m}, Ga⁶⁸, Cu⁶⁴ and radioactive isotopes of Lu, and Th²²⁷.

25

3. The immunoconjugate according to claim 1 or 2, wherein at least 2 molecules of antibody according to the invention are internalized by one molecule of LAMP1 expressed at the surface of a cancer cell.

- 30 4. The immunoconjugate according to any one of claims 1 to 3, wherein said antibody binds to a domain consisting of first to third loops of human and *Macaca fascicularis* LAMP1 proteins; wherein the domain consisting of the first to third loops of human LAMP1 protein consists of amino acids Ala29 to Ile309 of SEQ ID NO: 24 and the domain consisting of the first to third loops of *Macaca fascicularis* LAMP1 protein
35 consists of amino acids Ala27 to Thr307 of SEQ ID NO: 39.

5. The immunoconjugate according to any one of claims 1 to 4, wherein the antibody binds to a first luminal domain of human and *Macaca fascicularis* LAMP1 proteins; wherein the first luminal domain of human LAMP1 protein consists of amino acids at positions Ala29 to Arg195 of SEQ ID NO: 24 and the first luminal domain of *Macaca fascicularis* LAMP1 protein consists of amino acids at positions Ala27 to Arg193 of SEQ ID NO: 39.

6. The immunoconjugate according to any one of claims 1 to 5, wherein the antibody competes for binding to the first luminal domain of human and *Macaca fascicularis* LAMP1 proteins with an antibody comprising the variable heavy and light chains of

- (i) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 1 and a variable domain of light chain of sequence SEQ ID NO: 5; or
- (ii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 8 and a variable domain of light chain of sequence of sequence SEQ ID NO: 12; or
- (iii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 15 and a variable domain of light chain of sequence of sequence SEQ ID NO: 16; or
- (i) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence of sequence SEQ ID NO: 46; or
- (iv) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence of sequence SEQ ID NO: 51; or
- (v) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 53 and a variable domain of light chain of sequence of sequence SEQ ID NO: 56; or
- (vi) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 54 and a variable domain of light chain of sequence of sequence SEQ ID NO: 57; or
- (vii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 55 and a variable domain of light chain of sequence of sequence SEQ ID NO: 58.

7. The immunoconjugate according to any one of claims 1 to 6, wherein the antibody comprises:

- 5 (i) a CDR1-H of sequence SEQ ID NO: 2 or a sequence differing from SEQ ID NO: 2 by one amino acid substitution, a CDR2-H of sequence SEQ ID NO: 3 or a sequence differing from SEQ ID NO: 3 by one amino acid substitution, and a CDR3-H of sequence SEQ ID NO: 4 or a sequence differing from SEQ ID NO: 4 by one amino acid substitution; or
- 10 a CDR1-L of sequence SEQ ID NO: 6 or a sequence differing from SEQ ID NO: 6 by one amino acid substitution, a CDR2-L of sequence DTS or a sequence differing from DTS by one amino acid substitution and a CDR3-L of sequence SEQ ID NO: 7 or a sequence differing from SEQ ID NO: 7 by one amino acid substitution; or
- 15 (ii) a CDR1-H of sequence SEQ ID NO: 9 or a sequence differing from SEQ ID NO: 9 by one amino acid substitution, a CDR2-H of sequence SEQ ID NO: 10 or a sequence differing from SEQ ID NO: 10 by one amino acid substitution, a CDR3-H of sequence SEQ ID NO: 11 or a sequence differing from SEQ ID NO: 11 by one amino acid substitution; or
- 20 a CDR1-L of sequence SEQ ID NO: 13 or a sequence differing from SEQ ID NO: 13 by one amino acid substitution, a CDR2-L of sequence AAS or a sequence differing from AAS by one amino acid substitution, and a CDR3-L of sequence SEQ ID NO: 14 or a sequence differing from SEQ ID NO: 14 by one amino acid substitution; or
- 25 (iii) a CDR1-H of sequence SEQ ID NO: 43 or a sequence differing from SEQ ID NO: 43 by one amino acid substitution, a CDR2-H of sequence SEQ ID NO: 44 or a sequence differing from SEQ ID NO: 44 by one amino acid substitution, and a CDR3-H of sequence SEQ ID NO: 45 or a sequence differing from SEQ ID NO: 45 by one amino acid substitution; or
- 30 a CDR1-L of sequence SEQ ID NO: 47 or a sequence differing from SEQ ID NO: 47 by one amino acid substitution, a CDR2-L of sequence YTS or a sequence differing from YTS by one amino acid substitution, and a CDR3-L of sequence SEQ ID NO: 48 or SEQ ID NO: 52 or a sequence differing from SEQ ID NO: 48 or SEQ ID NO: 52 by one amino acid substitution.
- 35

8. The immunoconjugate according to claim 7, wherein said amino acid substitution is a conservative amino acid substitution.

9. The immunoconjugate according to any one of claims 1 to 8, wherein the antibody
5 comprises:

- (i) a CDR1-H of sequence SEQ ID NO: 2, a CDR2-H of sequence SEQ ID NO: 3, a CDR3-H of sequence SEQ ID NO: 4, a CDR1-L of sequence SEQ ID NO: 6, a CDR2-L of sequence DTS, and a CDR3-L of sequence SEQ ID NO: 7; or
- 10 (ii) a CDR1-H of sequence SEQ ID NO: 9, a CDR2-H of sequence SEQ ID NO: 10, a CDR3-H of sequence SEQ ID NO: 11, a CDR1-L of sequence SEQ ID NO: 13, a CDR2-L of sequence AAS, and a CDR3-L of sequence SEQ ID NO: 14; or
- (iii) a CDR1-H of sequence SEQ ID NO: 43, a CDR2-H of sequence SEQ ID NO: 44, a CDR3-H of sequence SEQ ID NO: 45, a CDR1-L of sequence
15 SEQ ID NO: 47, a CDR2-L of sequence YTS, and a CDR3-L of sequence SEQ ID NO: 48 or SEQ ID NO: 52; or
- (iv) a fragment of an antibody as defined in (i), (ii), or (iii).

20 10. The immunoconjugate according to any one of claims 1 to 9, wherein the antibody comprises:

- (i) a variable domain of heavy chain of sequence SEQ ID NO: 1 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 5, or a sequence at least
25 85% identical thereto; or
- (ii) a variable domain of heavy chain of sequence SEQ ID NO: 8, or a sequence at least 85% identical thereto, or a variable domain of light chain of sequence of sequence SEQ ID NO: 12, or a sequence at least 85% identical thereto; or
- 30 (iii) a variable domain of heavy chain of sequence SEQ ID NO: 15, or a sequence at least 85% identical thereto, or a variable domain of light chain of sequence of sequence SEQ ID NO: 16, or a sequence at least 85% identical thereto; or
- (iv) a variable domain of heavy chain of sequence SEQ ID NO: 42, or a
35 sequence at least 85% identical thereto, or a variable domain of light

- chain of sequence of sequence SEQ ID NO: 46 or SEQ ID NO: 51, or a sequence at least 85% identical thereto, or
- 5 (v) a variable domain of heavy chain of sequence SEQ ID NO: 53 or a sequence at least 85% identical thereto and/or a variable domain of light chain of sequence of sequence SEQ ID NO: 56, or a sequence at least 85% identical thereto; or
- (vi) a variable domain of heavy chain of sequence SEQ ID NO: 54 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 57, or a sequence at least 10 85% identical thereto; or
- (vii) a variable domain of heavy chain of sequence SEQ ID NO: 55 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 58, or a sequence at least 15 85% identical thereto.
11. The immunoconjugate according to any one of claims 1 to 10, wherein the antibody does not significantly cross-react with human LAMP2 (SEQ ID NO: 40).
12. The immunoconjugate according to any one of claims 1 to 11, wherein the antibody 20 has an affinity measured via flow cytometry for human LAMP 1 and *Macaca fascicularis* LAMP1 expressed on the cell surface of a recombinant cell line, which is $\leq 35\text{nM}$.
13. The immunoconjugate according to any one of claims 1 to 12 wherein the antibody is a chimeric or a humanised antibody.
- 25 14. The immunoconjugate according to any one of claims 1 to 13, wherein the antibody comprises:
- i) a heavy chain of sequence SEQ ID NO: 17 or a light chain of sequence SEQ ID NO: 18; or
- 30 ii) a heavy chain of sequence SEQ ID NO: 19 or a light chain of sequence SEQ ID NO: 20; or
- iii) a heavy chain of sequence SEQ ID NO: 21 or a light chain of sequence SEQ ID NO: 22; or
- iv) a heavy chain of sequence SEQ ID NO: 49 or a light chain of sequence SEQ ID NO: 50, or
- 35

- v) a heavy chain of sequence SEQ ID NO: 49 or a light chain of sequence SEQ ID NO: 81, or
- vi) a heavy chain of sequence SEQ ID NO: 60 or a light chain of sequence SEQ ID NO: 59; or
- 5 vii) a heavy chain of sequence SEQ ID NO: 62 or a light chain of sequence SEQ ID NO: 61; or
- Viii) a heavy chain of sequence SEQ ID NO: 64 or a light chain of sequence SEQ ID NO: 63.
- 10 15. The immunoconjugate according to any one of claims 1 to 3, wherein the antibody binds to the fourth loop of human and *Macaca fascicularis* LAMP1 proteins; wherein the fourth loop of human LAMP1 protein consists of amino acids at positions Leu310 to Met382 of SEQ ID NO: 24 and the fourth loop of *Macaca fascicularis* LAMP1 protein consists of amino acids at positions Leu 308 to Met380 of SEQ ID NO: 39.
- 15 16. The immunoconjugate according to claim 15 wherein the antibody binds to a region of Loop 4 comprising the amino acids 360 to 375 of human LAMP1 that consists of sequences SEQ ID NO: 82.
- 20 17. The immunoconjugate according to claims 15 or 16, wherein the antibody comprises a CDR1-H of sequence SEQ ID NO: 83, a CDR2-H of sequence SEQ ID NO: 84, a CDR3-H of sequence SEQ ID NO: 85, a CDR1-L of sequence SEQ ID NO: 86, a CDR2-L of sequence NAK, and a CDR3-L of sequence SEQ ID NO: 87.
- 25 18. The immunoconjugate according to any one of claims 15 to 17, wherein the antibody comprises a variable domain of heavy chain of sequence SEQ ID NO: 88 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 89, or a sequence at least 85% identical thereto.
- 30 19. The immunoconjugate according to any one of claims 15 to 18, wherein the antibody is a chimeric or a humanised antibody.
20. The immunoconjugate according to any one of claims 1 to 19, wherein the antibody is an antibody fragment.

21. The immunoconjugate according to any one of claims 1 to 20, wherein the antibody is a fragment selected from the group consisting of Fv, Fab, F(ab')₂, Fab', dsFv, (dsFv)₂, scFv, sc(Fv)₂, diabodies and VHH.

5 22. The immunoconjugate according to any one of claims 1 to 21, wherein the antibody is a bispecific or a multispecific antibody.

23. The immunoconjugate according to any one of claims 1 to 22, wherein said at least one growth inhibitory agent is a cytotoxic agent or a radioactive isotope.

10

24. The immunoconjugate according to any one of claims 1 and 2 to 23, wherein said at least one growth inhibitory agent is selected from the group consisting of chemotherapeutic agents, enzymes, antibiotics, toxins, taxoids, vincas, taxanes, maytansinoid or maytansinoid analogs, tomaymycin or pyrrolobenzodiazepine derivatives, cryptophycin derivatives, leptomycin derivatives, auristatin or dolastatin analogs, prodrugs, topoisomerase II inhibitors, DNA alkylating agents, anti-tubulin agents, and CC-1065 or CC-1065 analogs.

15

25. The immunoconjugate according to any one of claims 1 and 2 to 23, wherein said at least one growth inhibitory agent is selected from the group consisting of At²¹¹, Ac²²⁵, Bi²¹², Er¹⁶⁹, I¹³¹, I¹²⁴, I¹²⁵, Y⁹⁰, In¹¹¹, P³², Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Sr⁸⁹, Zr⁸⁹, Tc^{99m}, Ga⁶⁸, Cu⁶⁴, radioactive isotopes of Lu, and Th²²⁷.

20

26. The immunoconjugate according to any one of claims 1 to 25, wherein said at least one growth inhibitory agent is

25

(i) a cytotoxic agent selected from the group consisting of enzymes other than from pokeweed antiviral protein; antibiotics other than from bleomycin and mitomycin; toxins of bacterial, fungal, or animal origin or of plant origin other than from abrin and ricin, including fragments and/or variants thereof; a drug or a pro-drug of a compound consisting in an anti-tubulin agent, a maytansinoid or maytansinoid analog, a taxoid or taxane other than from paclitaxel (Taxol), a vinca-alkaloid other than from vindesine, vincristine and vinblastine, a cryptophycin derivative, an auristatin or dolastatin analog; a DNA alkylating agent other than from BCNU and cyclophosphamide, a tomaymycin or pyrrolobenzodiazepine derivative, a CC-1065 or CC-1065 analog; a leptomycin

30

35

derivative ; a, topoisomerase II inhibitors other than doxorubicin (adriamycin) and etoposide, a RNA polymerase II inhibitor, alpha-amanitin, or

(ii) a radioactive isotopes selected from the group consisting of At²¹¹, Ac²²⁵, Bi²¹³, Pb²¹², Er¹⁶⁹, I¹²⁴, I¹²⁵, In¹¹¹, P³², Re¹⁸⁶, Sm¹⁵³, Sr⁸⁹, Zr⁸⁹, Tc^{99m}, Ga⁶⁸, Cu⁶⁴ and radioactive isotopes of Lu such as Lu¹⁷⁷, and Th²²⁷.

27. The immunoconjugate conjugate according to any one of claims 1 to 26, wherein said growth inhibitory agent is (*N*²-deacetyl-*N*²-(3-mercapto-1-oxopropyl)-maytansine) DM1 or *N*²-deacetyl-*N*²-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4).

28. The immunoconjugate according to any one of the claims 1 to 27, wherein the antibody is covalently attached via a cleavable or non-cleavable linker to the at least one growth inhibitory agent.

29. The immunoconjugate according to claim 28, wherein said linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(Pyridin-2-yl)disulfanyl-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).

30. The immunoconjugate according to claim 29, wherein said linker is N-succinimidyl pyridyldithiobutyrate (SPDB) and the growth inhibitory agent is *N*²-deacetyl-*N*²-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4).

31. The immunoconjugate according to claim 30, wherein said linker is 4-(Pyridin-2-yl)disulfanyl-2-sulfo-butyric acid (sulfo-SPDB) and the growth inhibitory agent is *N*²-deacetyl-*N*²-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4).

32. The immunoconjugate according to claim 29, wherein said linker is succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and the growth inhibitory agent is *N*²-deacetyl-*N*²-(3-mercapto-1-oxopropyl)-maytansine (DM1).

33. The immunoconjugate according to any one of claims 27 to 32, wherein the immunoconjugate is characterised by a drug-to-antibody ratio (DAR) ranging from 1 to 10, preferably between 2 to 5, more preferably between 3 to 4, the DAR being calculated

from the ratio of the drug concentration to that of the antibody :

$$\text{DAR} = c_D / c_A$$

wherein

$$c_D = [(\epsilon_{A280} \times A_{252}) - (\epsilon_{A252} \times A_{280})] / [(\epsilon_{D252} \times \epsilon_{A280}) - (\epsilon_{A252} \times \epsilon_{D280})]$$

5

$$c_A = [A_{280} - (c_D \times \epsilon_{D280})] / \epsilon_{A280}$$

and

ϵ_{D252} and ϵ_{D280} are respectively the molar extinction coefficients of the drug at 252 nm and 280 nm;

10

ϵ_{A252} and ϵ_{A280} are respectively the molar extinction coefficients of the antibody at 252 nm and 280 nm;

(A_{252}) and A_{280} are respectively the absorbances for the conjugate at 252 nm (A_{252}) and at 280 nm (A_{280}), measured using a classic spectrophotometer apparatus.

15

34. An isolated antibody which binds to the first luminal domain of human and *Macaca fascicularis* LAMP1 proteins, wherein the first luminal domain of human LAMP1 is defined by the amino acids at positions Ala29 to Arg195 of SEQ ID NO: 24, and the first luminal domain of *Macaca fascicularis* LAMP1 protein is defined by the amino acids at positions Ala27 to Arg193 of SEQ ID NO: 39.

20

35. The isolated antibody according to claim 34, which competes for binding to the first luminal domain of human and *Macaca fascicularis* LAMP1 proteins with an antibody comprising the variable heavy and light chains of

25

(i) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 1 and a variable domain of light chain of sequence of sequence SEQ ID NO: 5; or

(ii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 8 and a variable domain of light chain of sequence of sequence SEQ ID NO: 12; or

30

(iii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 15 and a variable domain of light chain of sequence of sequence SEQ ID NO: 16; or

35

(ii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence of sequence SEQ ID NO: 46; or

- (iv) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence SEQ ID NO: 51; or
- 5 (v) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 53 and a variable domain of light chain of sequence SEQ ID NO: 56, or
- (vi) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 54 and a variable domain of light chain of sequence SEQ ID NO: 57, or
- 10 (vii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 55 and a variable domain of light chain of sequence SEQ ID NO: 58.

36. The isolated antibody according to claim 34 or 35, which comprises
- 15 (i) a CDR1-H of sequence SEQ ID NO: 2, a CDR2-H of sequence SEQ ID NO: 3, and a CDR3-H of sequence SEQ ID NO: 4; or
a CDR1-L of sequence SEQ ID NO: 6, a CDR2-L of sequence DTS, and
a CDR3-L of sequence SEQ ID NO: 7; or
- (ii) a CDR1-H of sequence SEQ ID NO: 9, a CDR2-H of sequence SEQ ID
20 NO: 10, a CDR3-H of sequence SEQ ID NO: 11; or
a CDR1-L of sequence SEQ ID NO: 13, a CDR2-L of sequence AAS,
and a CDR3-L of sequence SEQ ID NO: 14; or
- (iii) a CDR1-H of sequence SEQ ID NO: 43, a CDR2-H of sequence SEQ ID
NO: 44, and a CDR3-H of sequence SEQ ID NO: 45, or
- 25 a CDR1-L of sequence SEQ ID NO: 47, a CDR2-L of sequence YTS,
and a CDR3-L of sequence SEQ ID NO: 48 or SEQ ID NO: 52.

37. The isolated antibody according to any one of claims 34 to 36, which is as defined in claims 5 to 15.

30

38. An isolated antibody which binds to the fourth loop of human and *Macaca fascicularis* LAMP1 proteins; wherein the fourth loop of human LAMP1 protein consists of amino acids at positions Leu310 to Met382 of SEQ ID NO: 24 and the fourth loop of *Macaca fascicularis* LAMP1 protein consists of amino acids at positions Leu 308 to Met380 of
35 SEQ ID NO: 39.

39. The isolated antibody according to claim 38, wherein the antibody binds to a region of Loop 4 comprising the amino acids 360 to 375 of human LAMP1 that consists of sequences SEQ ID NO: 82.

5

40. The isolated antibody according to claim 38 or 39, wherein the antibody comprises a CDR1-H of sequence SEQ ID NO: 83, a CDR2-H of sequence SEQ ID NO: 84, a CDR3-H of sequence SEQ ID NO: 85, or a CDR1-L of sequence SEQ ID NO: 86, a CDR2-L of sequence NAK, and a CDR3-L of sequence SEQ ID NO: 87.

10

41. The isolated antibody according to any one of claims 38 to 40, wherein the antibody comprises a variable domain of heavy chain of sequence SEQ ID NO: 88 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 89, or a sequence at least 85% identical thereto.

15

42. An isolated anti-LAMP-1 antibody which comprises:

(vii) a CDR1-H of sequence SEQ ID NO: 2, a CDR2-H of sequence SEQ ID NO: 3, and a CDR3-H of sequence SEQ ID NO: 4; or
a CDR1-L of sequence SEQ ID NO: 6, a CDR2-L of sequence DTS, and
a CDR3-L of sequence SEQ ID NO: 7; or

20

(viii) a CDR1-H of sequence SEQ ID NO: 9, a CDR2-H of sequence SEQ ID NO: 10, a CDR3-H of sequence SEQ ID NO: 11; or
a CDR1-L of sequence SEQ ID NO: 13, a CDR2-L of sequence AAS,
and a CDR3-L of sequence SEQ ID NO: 14; or

25

(ix) a CDR1-H of sequence SEQ ID NO: 43, a CDR2-H of sequence SEQ ID NO: 44, and a CDR3-H of sequence SEQ ID NO: 45, or
a CDR1-L of sequence SEQ ID NO: 47, a CDR2-L of sequence YTS,
and a CDR3-L of sequence SEQ ID NO: 48 or SEQ ID NO: 52; or

30

(x) CDR1-H of sequence SEQ ID NO: 83, a CDR2-H of sequence SEQ ID NO: 84, a CDR3-H of sequence SEQ ID NO: 85, or a CDR1-L of sequence SEQ ID NO: 86, a CDR2-L of sequence NAK, and a CDR3-L of sequence SEQ ID NO: 87; or a heavy chain of sequence SEQ ID NO: 60 or a light chain of sequence SEQ ID NO: 59; or

35

(xi) a heavy chain of sequence SEQ ID NO: 62 or a light chain of sequence SEQ ID NO: 61; or

- (xii) a heavy chain of sequence SEQ ID NO: 64 or a light chain of sequence SEQ ID NO: 63.

- 5 43. The isolated antibody according to any one of claims 38 to 42, wherein said antibody is labelled with a detectable molecule or substance.
44. A pharmaceutical composition comprising an immunoconjugate according to any one of claims 1 to 33, or an antibody according to any one of claims 34 to 42, and a pharmaceutically acceptable carrier.
- 10 45. An immunoconjugate according to any one of claims 1 to 34, or an antibody according to any one of claims 34 to 42, or a pharmaceutical composition according to claim 44, for use for the treatment of cancer.
- 15 46. The immunoconjugate, antibody or pharmaceutical composition for the use according to claim 45, wherein the cancer is colon cancer adenocarcinoma, gastrointestinal tumors, vital organs tumors, reproductive organ tumors, or skin, larynx or soft tissue tumor.
- 20 47. An antibody according to any one of claims 34 to 43 for use for *ex vivo* detecting LAMP1 expression in biological sample of a subject.
48. An antibody according to any one of claims 34 to 43 for use for *in vivo* detecting LAMP1 expression in a subject.
- 25 49. The antibody for the use according to claim 47 or 48, wherein said antibody is labelled with a detectable molecule or substance.
50. The antibody for the use according to any one of claims 46 to 49, wherein said use is for diagnosing the presence of a cancer in a subject, determining susceptibility of a patient having cancer to a therapeutic agent targeting LAMP1, or monitoring effectiveness of anti-LAMP1 cancer therapy or detecting cancer relapse after anti-LAMP1 cancer therapy.
- 30 51. An isolated nucleic acid comprising a sequence encoding an antibody according to any one of claims 34 to 42.
- 35

52. A host cell which has been transformed by a nucleic acid according to claim 51.

53. An *in vitro* method of selecting patients with cancer who are likely to respond to anti-LAMP1 therapy, wherein said method comprises:

a. determining, in a biological sample of a patient with cancer which includes cancer cells, if said patient harbors a LAMP1 gene copy number gain; and

b. selecting the patient based on the presence of LAMP1 gene copy number gain,

and wherein said patient is selected as likely to respond to anti-LAMP1 therapy if said patient harbors a LAMP1 gene copy number gain.

54. The method according to claim 53, which further comprises determining if LAMP1 is expressed at the surface of cancer cells of the patient, and wherein i) said patient is selected as likely to respond to anti-LAMP1 therapy if said patient harbors a LAMP1 gene copy number gain and if said cancer cells of the patient express LAMP1 at their surface.

55. The method according to claim 53 or 54, wherein said cancer is selected from the group consisting of bladder, breast, cervical, colorectal, glioblastoma, head and neck, kidney, liver, lung, glioma, ovarian, pancreatic, prostate, stomach, thyroid, and uterine cancer.

56. The method according to any one of claims 53 to 55, wherein said cancer is selected from the group consisting of bladder, cervical, colorectal, glioblastoma, head and neck, kidney, liver, lung, glioma, ovarian, pancreatic, prostate, stomach, thyroid, and uterine cancer.

57. The method according to any one of claims 53 to 56, wherein said cancer is colorectal or lung cancer.

58. A method according to any one of claims 53 to 57, wherein mean LAMP1 gene copy number in cancer cells is ≥ 2.5 .

59. Method according to any one of claims 53 to 58, wherein mean LAMP1 gene copy

number in cancer cells is > 5 .

60. A method according to any one of claims 53 to 59, wherein LAMP1 gene copy number gain is determined with a method selected from the group consisting of
5 Fluorescence In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), New Generation Sequencing (NGS) or Polymerase Chain Reaction (PCR).

61. A method according to claim 60, wherein LAMP1 gene copy number gain is determined by Comparative Genomic Hybridization (CGH).
10

62. A method according to claim 60, wherein LAMP1 gene copy number gain is determined by Polymerase Chain Reaction (PCR).

63. A method according to claim 60, wherein LAMP1 gene copy number gain is determined by Fluorescence In Situ Hybridization (FISH).
15

64. A method according to claim 60, wherein LAMP1 gene copy number gain is determined by New Generation Sequencing (NGS).

20 65. An anti-LAMP1 therapeutic agent for use for treating cancer in a patient harboring LAMP1 gene copy number gain in cancer cells.

66. The anti-LAMP1 therapeutic agent for the use according to claim 65, wherein said patient harboring LAMP1 gene copy number gain in cancer cells has been selected by a
25 method according to any one of claims 53 to 64.

67. The anti-LAMP1 therapeutic agent for the use according to claim 65, which use comprises selecting said patient harboring LAMP1 gene copy number gain in cancer cells by a method according to any one of claims 53 to 64.
30

68. The anti-LAMP1 therapeutic agent for the use according to any one of claims 65 to 67, wherein said anti-LAMP1 therapeutic agent is an anti-LAMP1 antibody according to any one of claims 34 to 42 or an immunoconjugate comprising an anti-LAMP1 antibody and at least one growth inhibitory agent according to any one of claims 1 to 33.
35

CLAIMS

1. An immunoconjugate comprising an antibody which:
 - a) binds to the domain consisting of the first to third loops of human LAMP1 protein which consists of amino acids Ala29 to Ile309 of SEQ ID NO: 24, and
 - b) is linked or conjugated to at least one growth inhibitory agent.
2. The immunoconjugate according to claim 1, wherein the antibody binds to a first luminal domain of human LAMP1 protein; wherein the first luminal domain of human LAMP1 protein consists of amino acids at positions Ala29 to Arg195 of SEQ ID NO: 24.
3. The immunoconjugate according to any one of claims 1 or 2, wherein the antibody competes for binding to the first luminal domain of human LAMP1 proteins with an antibody comprising the variable heavy and light chains of
 - (i) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 1 and a variable domain of light chain of sequence of sequence SEQ ID NO: 5; or
 - (ii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 8 and a variable domain of light chain of sequence of sequence SEQ ID NO: 12; or
 - (iii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 15 and a variable domain of light chain of sequence of sequence SEQ ID NO: 16; or
 - (i) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence of sequence SEQ ID NO: 46; or
 - (iv) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence of sequence SEQ ID NO: 51; or
 - (v) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 53 and a variable domain of light chain of sequence of sequence SEQ ID NO: 56; or
 - (vi) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 54 and a variable domain of light chain of sequence of sequence SEQ ID NO: 57; or
 - (vii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 55 and a variable domain of light chain of sequence of sequence

SEQ ID NO: 58.

4. The immunoconjugate according to any one of claims 1 to 3 wherein the antibody comprises:

- (i) a CDR1-H of sequence SEQ ID NO: 2 or a sequence differing from SEQ ID NO: 2 by one amino acid substitution, a CDR2-H of sequence SEQ ID NO: 3 or a sequence differing from SEQ ID NO: 3 by one amino acid substitution, and a CDR3-H of sequence SEQ ID NO: 4 or a sequence differing from SEQ ID NO: 4 by one amino acid substitution; and
a CDR1-L of sequence SEQ ID NO: 6 or a sequence differing from SEQ ID NO: 6 by one amino acid substitution, a CDR2-L of sequence DTS or a sequence differing from DTS by one amino acid substitution and a CDR3-L of sequence SEQ ID NO: 7 or a sequence differing from SEQ ID NO: 7 by one amino acid substitution; or
- (ii) a CDR1-H of sequence SEQ ID NO: 9 or a sequence differing from SEQ ID NO: 9 by one amino acid substitution, a CDR2-H of sequence SEQ ID NO: 10 or a sequence differing from SEQ ID NO: 10 by one amino acid substitution, a CDR3-H of sequence SEQ ID NO: 11 or a sequence differing from SEQ ID NO: 11 by one amino acid substitution; or
a CDR1-L of sequence SEQ ID NO: 13 or a sequence differing from SEQ ID NO: 13 by one amino acid substitution, a CDR2-L of sequence AAS or a sequence differing from AAS by one amino acid substitution, and a CDR3-L of sequence SEQ ID NO: 14 or a sequence differing from SEQ ID NO: 14 by one amino acid substitution; or
- (iii) a CDR1-H of sequence SEQ ID NO: 43 or a sequence differing from SEQ ID NO: 43 by one amino acid substitution, a CDR2-H of sequence SEQ ID NO: 44 or a sequence differing from SEQ ID NO: 44 by one amino acid substitution, and a CDR3-H of sequence SEQ ID NO: 45 or a sequence differing from SEQ ID NO: 45 by one amino acid substitution; or
a CDR1-L of sequence SEQ ID NO: 47 or a sequence differing from SEQ ID NO: 47 by one amino acid substitution, a CDR2-L of sequence YTS or a sequence differing from YTS by one amino acid substitution, and a CDR3-L of sequence SEQ ID NO: 48 or SEQ ID NO: 52 or a sequence differing from SEQ ID NO: 48 or SEQ ID NO: 52 by one amino acid substitution.

5. The immunoconjugate according to claim 4, wherein said amino acid substitution is a conservative amino acid substitution.

6. The immunoconjugate according to any one of claims 1 to 5, wherein the antibody comprises:

- (i) a CDR1-H of sequence SEQ ID NO: 2, a CDR2-H of sequence SEQ ID NO: 3, a CDR3-H of sequence SEQ ID NO: 4, a CDR1-L of sequence SEQ ID NO: 6, a CDR2-L of sequence DTS, and a CDR3-L of sequence SEQ ID NO: 7; or
- (ii) a CDR1-H of sequence SEQ ID NO: 9, a CDR2-H of sequence SEQ ID NO: 10, a CDR3-H of sequence SEQ ID NO: 11, a CDR1-L of sequence SEQ ID NO: 13, a CDR2-L of sequence AAS, and a CDR3-L of sequence SEQ ID NO: 14; or
- (iii) a CDR1-H of sequence SEQ ID NO: 43, a CDR2-H of sequence SEQ ID NO: 44, a CDR3-H of sequence SEQ ID NO: 45, a CDR1-L of sequence SEQ ID NO: 47, a CDR2-L of sequence YTS, and a CDR3-L of sequence SEQ ID NO: 48 or SEQ ID NO: 52; or
- (iv) a fragment of an antibody as defined in (i), (ii), or (iii).

7. The immunoconjugate according to any one of claims 1 to 6, wherein the antibody comprises:

- (i) a variable domain of heavy chain of sequence SEQ ID NO: 1 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 5, or a sequence at least 85% identical thereto; or
- (ii) a variable domain of heavy chain of sequence SEQ ID NO: 8, or a sequence at least 85% identical thereto, or a variable domain of light chain of sequence of sequence SEQ ID NO: 12, or a sequence at least 85% identical thereto; or
- (iii) a variable domain of heavy chain of sequence SEQ ID NO: 15, or a sequence at least 85% identical thereto, or a variable domain of light chain of sequence of sequence SEQ ID NO: 16, or a sequence at least 85% identical thereto; or
- (iv) a variable domain of heavy chain of sequence SEQ ID NO: 42, or a sequence at least 85% identical thereto, or a variable domain of light chain of sequence of sequence SEQ ID NO: 46 or SEQ ID NO: 51, or a sequence at least 85% identical thereto, or
- (v) a variable domain of heavy chain of sequence SEQ ID NO: 53 or a sequence at least 85% identical thereto and/or a variable domain of light chain of sequence of sequence SEQ ID NO: 56, or a sequence at least 85%

identical thereto; or

- (vi) a variable domain of heavy chain of sequence SEQ ID NO: 54 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 57, or a sequence at least 85% identical thereto; or
- (vii) a variable domain of heavy chain of sequence SEQ ID NO: 55 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 58, or a sequence at least 85% identical thereto.

8. The immunoconjugate according to any one of claims 1 to 7, wherein the antibody does not significantly cross-react with human LAMP2 (SEQ ID NO: 40).

9. The immunoconjugate according to any one of claims 1 to 8, wherein the antibody has an affinity measured via flow cytometry for human LAMP 1 expressed on the cell surface of a recombinant cell line, which is $\leq 35\text{nM}$.

10. The immunoconjugate according to any one of claims 1 to 9 wherein the antibody is a chimeric or a humanised antibody.

11. The immunoconjugate according to any one of claims 1 to 10, wherein the antibody comprises:

- i) a heavy chain of sequence SEQ ID NO: 17 or a light chain of sequence SEQ ID NO: 18; or
- ii) a heavy chain of sequence SEQ ID NO: 19 or a light chain of sequence SEQ ID NO: 20; or
- iii) a heavy chain of sequence SEQ ID NO: 21 or a light chain of sequence SEQ ID NO: 22; or
- iv) a heavy chain of sequence SEQ ID NO: 49 or a light chain of sequence SEQ ID NO: 50, or
- v) a heavy chain of sequence SEQ ID NO: 49 or a light chain of sequence SEQ ID NO: 81, or
- vi) a heavy chain of sequence SEQ ID NO: 60 or a light chain of sequence SEQ ID NO: 59; or
- vii) a heavy chain of sequence SEQ ID NO: 62 or a light chain of sequence SEQ ID NO: 61; or
- Viii) a heavy chain of sequence SEQ ID NO: 64 or a light chain of sequence SEQ ID

NO: 63.

12. The immunoconjugate according to any one of claims 1 to 11, wherein the antibody is an antibody fragment.

13. The immunoconjugate according to any one of claims 1 to 12 wherein the antibody is a fragment selected from the group consisting of Fv, Fab, F(ab')₂, Fab', dsFv, (dsFv)₂, scFv, sc(Fv)₂, diabodies and VHH.

14. The immunoconjugate according to any one of claims 1 to 13, wherein the antibody is a bispecific antibody.

15. The immunoconjugate according to any one of claims 1 to 13, wherein the antibody is a multispecific antibody.

16. The immunoconjugate according to any one of claims 1 to 15, wherein said at least one growth inhibitory agent is a cytotoxic agent or a radioactive isotope.

17. The immunoconjugate according to any one of claims 1 to 16, wherein said at least one growth inhibitory agent is selected from the group consisting of chemotherapeutic agents, enzymes, antibiotics, toxins, taxoids, vincas, taxanes, maytansinoid or maytansinoid analogs, tomaymycin or pyrrolobenzodiazepine derivatives, cryptophycin derivatives, leptomycin derivatives, auristatin or dolastatin analogs, prodrugs, topoisomerase II inhibitors, DNA alkylating agents, anti-tubulin agents, and CC-1065 or CC-1065 analogs.

18. The immunoconjugate according to any one of claims 1 to 16, wherein said at least one growth inhibitory agent is selected from the group consisting of At²¹¹, Ac²²⁵, Bi²¹², Er¹⁶⁹, I¹³¹, I¹²⁴, I¹²⁵, Y⁹⁰, In¹¹¹, P³², Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Sr⁸⁹, Zr⁸⁹, Tc^{99m}, Ga⁶⁸, Cu⁶⁴, radioactive isotopes of Lu, and Th²²⁷.

19. The immunoconjugate according to any one of claims 1 to 16, wherein said at least one growth inhibitory agent is

(i) a cytotoxic agent selected from the group consisting of enzymes other than from pokeweed antiviral protein; antibiotics other than from bleomycin and mitomycin; toxins of bacterial, fungal, or animal origin or of plant origin other than from abrin and ricin, including fragments and/or variants thereof; a drug or a pro-drug of a compound

consisting in an anti-tubulin agent, a maytansinoid or maytansinoid analog, a taxoid or taxane other than from paclitaxel (Taxol), a vinca-alkaloid other than from vindesine, vincristine and vinblastine, a cryptophycin derivative, an auristatin or dolastatin analog; a DNA alkylating agent other than from BCNU and cyclophosphamide, a tomaymycin or pyrrolobenzodiazepine derivative, a CC-1065 or CC-1065 analog; a leptomycin derivative ; a, topoisomerase II inhibitors other than doxorubicin (adriamycin) and etoposide, a RNA polymerase II inhibitor, alpha-amanitin, or

(ii) a radioactive isotopes selected from the group consisting of At²¹¹, Ac²²⁵, Bi²¹³, Pb²¹², Er¹⁶⁹, I¹²⁴, I¹²⁵, In¹¹¹, P³², Re¹⁸⁶, Sm¹⁵³, Sr⁸⁹, Zr⁸⁹, Tc^{99m}, Ga⁶⁸, Cu⁶⁴ and radioactive isotopes of Lu such as Lu¹⁷⁷, and Th²²⁷.

20. The immunoconjugate according to any one of claims 1 to 16, wherein said growth inhibitory agent is (*N*^{2'}-deacetyl-*N*^{2'}-(3-mercapto-1-oxopropyl)-maytansine) DM1 or *N*^{2'}-deacetyl-*N*^{2'}-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4).

21. The immunoconjugate according to any one of the claims 1 to 20, wherein the antibody is covalently attached via a cleavable or non-cleavable linker to the at least one growth inhibitory agent.

22. The immunoconjugate according to claim 21, wherein said linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(Pyridin-2-yl)disulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).

23. The immunoconjugate according to claim 21, wherein said linker is N-succinimidyl pyridyldithiobutyrate (SPDB) and the growth inhibitory agent is *N*^{2'}-deacetyl-*N*^{2'}-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4).

24. The immunoconjugate according to claim 21, wherein said linker is 4-(Pyridin-2-yl)disulfanyl)-2-sulfo-butyric acid (sulfo-SPDB) and the growth inhibitory agent is *N*^{2'}-deacetyl-*N*^{2'}-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4).

25. The immunoconjugate according to claim 21, wherein said linker is succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and the growth inhibitory agent is *N*^{2'}-deacetyl-*N*^{2'}-(3-mercapto-1-oxopropyl)-maytansine (DM1).

26. The immunoconjugate according to any one of claims 1 to 25, wherein the

immunoconjugate is characterised by a drug-to-antibody ratio (DAR) ranging from 1 to 10, preferably between 2 to 5, more preferably between 3 to 4, the DAR being calculated from the ratio of the drug concentration to that of the antibody :

$$\text{DAR} = c_D / c_A$$

wherein

$$c_D = [(\epsilon_{A280} \times A_{252}) - (\epsilon_{A252} \times A_{280})] / [(\epsilon_{D252} \times \epsilon_{A280}) - (\epsilon_{A252} \times \epsilon_{D280})]$$

$$c_A = [A_{280} - (c_D \times \epsilon_{D280})] / \epsilon_{A280}$$

and

ϵ_{D252} and ϵ_{D280} are respectively the molar extinction coefficients of the drug at 252 nm and 280 nm;

ϵ_{A252} and ϵ_{A280} are respectively the molar extinction coefficients of the antibody at 252 nm and 280 nm;

(A_{252}) and A_{280} are respectively the absorbances for the conjugate at 252 nm (A_{252}) and at 280 nm (A_{280}), measured using a classic spectrophotometer apparatus.

27. The immunoconjugate according to claim 1 to 26, wherein at least 2 molecules of antibody according to the invention are internalized by one molecule of LAMP1 expressed at the surface of a cancer cell.
28. An immunoconjugate comprising an antibody which binds to human LAMP1 protein linked or conjugated to at least one growth inhibitory agent, wherein the antibody comprises:
 - (i) a CDR1-H of sequence SEQ ID NO: 2, a CDR2-H of sequence SEQ ID NO: 3, a CDR3-H of sequence SEQ ID NO: 4, a CDR1-L of sequence SEQ ID NO: 6, a CDR2-L of sequence DTS, and a CDR3-L of sequence SEQ ID NO: 7; or
 - (ii) a fragment of an antibody as defined in (i).
29. An immunoconjugate comprising an antibody linked or conjugated to at least one growth inhibitory agent, wherein the antibody comprises:
 - (i) a variable domain of heavy chain of sequence SEQ ID NO: 1 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 5, or a sequence at least 85% identical thereto; or
 - (ii) a variable domain of heavy chain of sequence SEQ ID NO: 53 or a sequence at least 85% identical thereto and/or a variable domain of light chain of sequence of sequence SEQ ID NO: 56, or a sequence at least 85% identical thereto; or

- (iii) a variable domain of heavy chain of sequence SEQ ID NO: 54 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 57, or a sequence at least 85% identical thereto; or
- (iv) a variable domain of heavy chain of sequence SEQ ID NO: 55 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 58, or a sequence at least 85% identical thereto.
- (v) or a fragment of an antibody as defined in (i) to (iv).

30. An isolated antibody which binds to the first luminal domain of human LAMP1 protein, wherein the first luminal domain of human LAMP1 is defined by the amino acids at positions Ala29 to Arg195 of SEQ ID NO: 24.

31. The isolated antibody according to claim 30, which competes for binding to the first luminal domain of human LAMP1 protein with an antibody comprising the variable heavy and light chains of

- (i) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 1 and a variable domain of light chain of sequence of sequence SEQ ID NO: 5; or
- (ii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 8 and a variable domain of light chain of sequence of sequence SEQ ID NO: 12; or
- (iii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 15 and a variable domain of light chain of sequence of sequence SEQ ID NO: 16; or
- (ii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence of sequence SEQ ID NO: 46; or
- (iv) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 42 and a variable domain of light chain of sequence of sequence SEQ ID NO: 51; or
- (v) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 53 and a variable domain of light chain of sequence of sequence SEQ ID NO: 56, or
- (vi) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 54 and a variable domain of light chain of sequence of sequence

SEQ ID NO: 57, or

- (vii) an antibody comprising a variable domain of heavy chain of sequence SEQ ID NO: 55 and a variable domain of light chain of sequence of sequence SEQ ID NO: 58.

32. The isolated antibody according to claim 30 or 31, which comprises

- (i) a CDR1-H of sequence SEQ ID NO: 2, a CDR2-H of sequence SEQ ID NO: 3, and a CDR3-H of sequence SEQ ID NO: 4; or
a CDR1-L of sequence SEQ ID NO: 6, a CDR2-L of sequence DTS, and a CDR3-L of sequence SEQ ID NO: 7; or
- (ii) a CDR1-H of sequence SEQ ID NO: 9, a CDR2-H of sequence SEQ ID NO: 10, a CDR3-H of sequence SEQ ID NO: 11; or
a CDR1-L of sequence SEQ ID NO: 13, a CDR2-L of sequence AAS, and a CDR3-L of sequence SEQ ID NO: 14; or
- (iii) a CDR1-H of sequence SEQ ID NO: 43, a CDR2-H of sequence SEQ ID NO: 44, and a CDR3-H of sequence SEQ ID NO: 45, or
a CDR1-L of sequence SEQ ID NO: 47, a CDR2-L of sequence YTS, and a CDR3-L of sequence SEQ ID NO: 48 or SEQ ID NO: 52.

33. An isolated antibody which binds to the fourth loop of human and *Macaca fascicularis* LAMP1 proteins; wherein the fourth loop of human LAMP1 protein consists of amino acids at positions Leu310 to Met382 of SEQ ID NO: 24 and the fourth loop of *Macaca fascicularis* LAMP1 protein consists of amino acids at positions Leu 308 to Met380 of SEQ ID NO: 39.

34. The isolated antibody according to claim 33, wherein the antibody binds to a region of Loop 4 comprising the amino acids 360 to 375 of human LAMP1 that consists of sequences SEQ ID NO: 82.

35. The isolated antibody according to claim 33 or 34, wherein the antibody comprises a CDR1-H of sequence SEQ ID NO: 83, a CDR2-H of sequence SEQ ID NO: 84, a CDR3-H of sequence SEQ ID NO: 85, or a CDR1-L of sequence SEQ ID NO: 86, a CDR2-L of sequence NAK, and a CDR3-L of sequence SEQ ID NO: 87.

36. The isolated antibody according to any one of claims 33 to 35, wherein the antibody comprises a variable domain of heavy chain of sequence SEQ ID NO: 88 or a sequence at least 85% identical thereto or a variable domain of light chain of sequence of sequence SEQ ID NO: 89, or a sequence at least 85% identical thereto.

37. A pharmaceutical composition comprising an immunoconjugate according to any one of claims 1 to 29, or an antibody according to any one of claims 30 to 36, and a pharmaceutically acceptable carrier.

38. An immunoconjugate according to any one of claims 1 to 29, or an antibody according to any one of claims 30 to 36, or a pharmaceutical composition according to claim 37, for use for the treatment of cancer.

39. The immunoconjugate, antibody or pharmaceutical composition for the use according to claim 38, wherein the cancer is colon cancer adenocarcinoma, gastrointestinal tumors, vital organs tumors, reproductive organ tumors, or skin, larynx or soft tissue tumor.

40. An antibody according to any one of claims 30 to 36 for use for *ex vivo* detecting LAMP1 expression in biological sample of a subject.

41. An antibody according to any one of claims 30 to 36 for use for *in vivo* detecting LAMP1 expression in a subject.

42. The antibody for the use according to claim 40 or 41, wherein said antibody is labelled with a detectable molecule or substance.

43. The antibody for the use according to any one of claims 40 or 41, wherein said use is for diagnosing the presence of a cancer in a subject, determining susceptibility of a patient having cancer to a therapeutic agent targeting LAMP1, or monitoring effectiveness of anti-LAMP1 cancer therapy or detecting cancer relapse after anti-LAMP1 cancer therapy.

44. An isolated nucleic acid comprising a sequence encoding an antibody according to any one of claims 30 to 36.

45. A host cell which has been transformed by a nucleic acid according to claim 44.

46. Use of effective amount of an immunoconjugate according to any one of claims 1 to 29, or an antibody according to any one of claims 30 to 36, or a pharmaceutical composition according to claim 37 for the manufacture of a medicament for treating a cancer.

47. The use according to claim 46 wherein said use comprises selecting patients with cancer who are likely to respond to anti-LAMP1 therapy by determining, in a biological sample of a patient with cancer which includes cancer cells, if said patient harbors a LAMP1 gene copy number gain.

48. The use according to claim 47, which further comprises determining if LAMP1 is expressed at the surface of cancer cells of the patient.

49. The use according to any one of claims 47 and 48, wherein LAMP1 gene copy number gain is determined with a method selected from the group consisting of Fluorescence In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), New Generation Sequencing (NGS) or Polymerase Chain Reaction (PCR).

50. An *in vitro* method of selecting patients with cancer who are likely to respond to anti-LAMP1 therapy, wherein said method comprises:

- a. determining, in a biological sample of a patient with cancer which includes cancer cells, if said patient harbors a LAMP1 gene copy number gain; and
- b. selecting the patient based on the presence of LAMP1 gene copy number gain,

wherein said patient is selected as likely to respond to anti-LAMP1 therapy if said patient harbors a LAMP1 gene copy number gain.